Open ‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

CONCLUSIONSAlisertib at 20 mg twice daily on days 1 to 7 with intravenous docetaxel at 75 mg/m2 on day 1 in a 21‐day cycle was well tolerated, and the combination demonstrated antitumor activity. Cancer 2016;122:2524–33. © 2016 American Cancer Society.

Source: Cancer - May 17, 2016 Category: Cancer & Oncology Authors: Julie N. Graff, Celestia S. Higano, Noah M. Hahn, Matthew H. Taylor, Bin Zhang, Xiaofei Zhou, Karthik Venkatakrishnan, E. Jane Leonard, John Sarantopoulos Tags: Original Article Source Type: research